1. Long-Term Monitoring of Infliximab Therapy for Perianal Fistulizing Crohn's Disease by Using Magnetic Resonance Imaging 
Konstantinos Karmiris, Didier Bielen, Dirk Vanbeckevoort, Séverine Vermeire, Georges Coremans, Paul Rutgeerts, Gert Van Assche 
Clinical Gastroenterology and Hepatology 
Volume 9, Issue 2, Pages e1 (February 2011)
DOI: /j.cgh
Copyright © 2011 AGA Institute Terms and Conditions

2. Figure 1
Clinical outcome of IFX therapy in our cohort of pfCD patients.
Clinical Gastroenterology and Hepatology 2011 9, e1DOI: ( /j.cgh )
Copyright © 2011 AGA Institute Terms and Conditions

3. Figure 2
MRI score change short-term, mid-term, and long-term in pfCD patients under IFX therapy.
Clinical Gastroenterology and Hepatology 2011 9, e1DOI: ( /j.cgh )
Copyright © 2011 AGA Institute Terms and Conditions

4. Figure 3
Individual MRI score change in the total cohort (A) and according to complete (B), partial (C), and absent (D) clinical response.
Clinical Gastroenterology and Hepatology 2011 9, e1DOI: ( /j.cgh )
Copyright © 2011 AGA Institute Terms and Conditions

5. Figure 4
MRI images of a perianal horseshoe fistula in a young male patient with CD before and 3 months and 1 year after IFX therapy. Note that the inflammatory component (T2 hyperintensity and collections) markedly improved, but that the fistula track is still present after 1 year.
Clinical Gastroenterology and Hepatology 2011 9, e1DOI: ( /j.cgh )
Copyright © 2011 AGA Institute Terms and Conditions

6. Supplementary Figure 1
Midterm MRI score change in patients in remission in comparison with those with draining fistulas.
Clinical Gastroenterology and Hepatology 2011 9, e1DOI: ( /j.cgh )
Copyright © 2011 AGA Institute Terms and Conditions